Nicox SA announced that results from its phase 3 clinical development program for NCX 470 will be presented at the upcoming American Glaucoma Society (AGS) annual meeting, taking place February 19–22, 2026, in Rancho Mirage, California. The presentations will include two podium presentations and one poster session highlighting efficacy, safety, and mechanistic data from advanced clinical studies.

NCX 470 is a novel nitric oxide-donating bimatoprost ophthalmic solution being developed for the treatment of open-angle glaucoma and ocular hypertension. The data to be presented include findings from the pivotal DENALI phase 3 trial and a phase 3b study evaluating aqueous humor dynamics.

AGS 2026 Presentation Highlights

Podium Presentations

  • Title: A Randomized Trial Comparing NCX 470 0.1%, a Nitric Oxide-Donating Bimatoprost, and Latanoprost 0.005% for Open-Angle Glaucoma or Ocular Hypertension: The DENALI Trial
    Session: Basic Science, Genetics, Novel Developments Paper Session
    Date & Time: Friday, February 20, 2026, at 10:15 a.m. (local time)
    Presenter: Dr. S. Asrani, Duke University Medical Center, Durham, North Carolina

  • Title: Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution (Nitric Oxide-Donating Bimatoprost): A Double-Masked, Placebo-Controlled, Phase 3b Clinical Trial
    Session: Basic Science, Genetics, Novel Developments Paper Session
    Date & Time: Friday, February 20, 2026, at 10:25 a.m. (local time)
    Presenter: Dr. A. Sit, Mayo Clinic, Rochester, Minnesota

Poster Presentation

  • Title: Outcomes in the United States Subgroup of the DENALI Trial: A Randomized Trial Comparing NCX 470 0.1%, a Nitric Oxide-Donating Bimatoprost, and Latanoprost 0.005% for Open-Angle Glaucoma or Ocular Hypertension
    Session: Poster Session
    Date & Time: Friday, February 20, 2026, from 7:30 a.m. to 8:30 a.m. (local time)
    Presenter: Dr. J. Bacharach, North Bay Eye Associates, Inc., Petaluma, California